E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Female patients with breast cancer shortly after surgery [pTNM classification: pT1-T4, pN0-N+ (0-9 positive lymph nodes), pM0] qualified for adjuvant chemotherapy according to FEC scheme as standard of care |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057654 |
E.1.2 | Term | Breast cancer female |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to investigate the influence of PS76A2 on quality of life in patients with breast cancer receiving adjuvant chemotherapy quantified by FACT-G questionnaire. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to investigate the effect of PS76A2 on QoL quantified by GLQ-8, Spitzer's uniscale, FACT-B (i.e. FACT-G including additional concerns for patients with breast cancer), and EORTC QLQ-C30 as well as the effect of PS76A2 on the course of chemotherapy, on the hematological profile, and on safety variables. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Female patient 2) Postsurgical condition of breast cancer with TNM classification - pT1mic, pT1a, 1b, 1c, 2, 3 or 4 - pN0, pN+ with a maximum of 9 positive axillar lymph nodes - pM0 3) Patient is eligible for adjuvant chemotherapy according to the following scheme as standard of care: FEC (minimum three to maximum six 3-week cycles) 4) Pre- or postmenopausal state 5) Age between 18 and 60 years (18 and 70 years included). 6) School education > 7 years 7) Oral and written informed consent to participate in the study according to ICH-GCP and applicable national law 8) Women of childbearing potential must use at least one highly effective method of birth control during the whole study |
|
E.4 | Principal exclusion criteria |
1) Inability to answer the quality of life scales. 2) Two-sided location of breast cancer at study enrolment. 3) Carcinoma in situ. 4) Concomitant malignancy at study enrolment. 5) Administration of prohibited concomitant medication at study enrolment. Note: The use of prohibited drugs during the study will induce the exclusion from the per protocol population. 6) Radiation therapy prior to or at study enrolment in a total dose of > 60 Gy. Note: The administration of radiation therapy during the study period is allowed as long as the total dose does not exceed 60 Gy. 7) Deviation from the planned course of screening period: - Interval between surgery and first day of chemotherapy (= Day 1; = S2) greater than 70 days - Interval between surgery and first day of chemotherapy less than 15 days - Interval between S0 and first day of chemotherapy less than 14 days - Screening Visit S1 outside Day –7 (± 1 day) - Screening Visit S2 outside Day 1
8) Known hypersensitivity to protein or mistletoe preparations 9) Chronic progressive infections (e.g. tuberculosis). 10) Auto-immune diseases 11) Alcohol abuse (> 50 g ethanol per day). 12) Nicotine abuse (> 20 cigarettes per day). 13) Pregnancy or breast feeding. 14) Participating in another clinical trial within 30 days before study enrolment, or concurrent participating in another clinical trial. 15) Other circumstances that make the investigator expect an incomplete study participation of the patient (e.g. planned removal). 16) Cancellation of informed consent to participate in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The aim of the primary statistical analysis is to prove the superiority of PS76A2 ('active') to 'placebo' in patients with breast cancer receiving adjuvant chemotherapy with regard to QoL measurements by means of FACT-G. The primary endpoint is a cumulated change variable based on differences versus baseline (S1, S2, S3) after 4 (3-week) chemotherapy cycles. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 20 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 20 |